Sentences with phrase «systems cancer biology»

Not exact matches

Edmonton native Orrell is an Oxford - trained mathematician and complex systems analyst who's explored particle accelerator design, weather forecasting, and cancer biology.

The company leverages its unique insights in cancer biology and the immune system to discover and develop novel oral small molecules that activate immune responses to eliminate cancer cells.

My cancer systems biology team at the University of California, Merced, is tackling diagnosis and treatment of therapy - resistant cancers by elucidating the network of changes within cells as a way to identify new drug targets and circumvent cancer resistance.

The plenary address titled «Punctuated Equilibrium Meets Cancer: Big Promise Requires Big Change» will draw from evolutionary biology's punctuated equilibrium theory to set out why stable systems such as cancer research sometimes require swift and fundamental change to adCancer: Big Promise Requires Big Change» will draw from evolutionary biology's punctuated equilibrium theory to set out why stable systems such as cancer research sometimes require swift and fundamental change to adcancer research sometimes require swift and fundamental change to advance.

The St. Laurent Institute, a non-profit medical research institute focused on the systems biology of disease, today announced in a study published in the July edition of Genome Biology, that genetic matter, previously ignored by the scientific community, may play an important role in cancer.

This webinar will discuss how integrated HCS imaging systems that have been coupled with novel computer modeling are being applied to systems biology, translational cancer research, and personalized medicine.

Areas covered range from basic studies into the biology of innate and adaptive immunity (immune cell development and differentiation, immunogenomics, systems immunology, structural immunology, antigen presentation, immunometabolism, and mucosal immunology) to immune contributions to health and disease (host defense, inflammation, cancer immunology, autoimmunity, allergy, transplantation, and immunodeficiency).

We use a combination of genomics, systems biology, biochemistry, bioinformatics and molecular biology to investigate the networks formed by RNA binding proteins, miRNAs and their target genes and evaluate their impact on biological processes, cancer and disease states.

There are currently 25 research groups in our school and areas of research in Biochemistry include membrane proteins, enzymology, folic acid biochemistry, structural biology, tRNA biology, neurochemistry, neurodegeneration, metabolism, systems biology, cancer biology, molecular parasitology, apoptosis and drug discovery.

The MGH Research Institute conducts the largest hospital - based research program in the nation, with an annual research budget of more than $ 800 million and major research centers in HIV / AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology.

NEW YORK and SEATTLE — April 5, 2018 — The Cancer Research Institute (CRI), Institute for Systems Biology (ISB) and Sage Bionetworks — three organizations on the forefront of cancer immunotherapy, systems biology and bioinformatics — today announced the release of the Cancer Research Institute iAtlas, a comprehensive web - based tool that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenviroCancer Research Institute (CRI), Institute for Systems Biology (ISB) and Sage Bionetworks — three organizations on the forefront of cancer immunotherapy, systems biology and bioinformatics — today announced the release of the Cancer Research Institute iAtlas, a comprehensive web - based tool that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvirSystems Biology (ISB) and Sage Bionetworks — three organizations on the forefront of cancer immunotherapy, systems biology and bioinformatics — today announced the release of the Cancer Research Institute iAtlas, a comprehensive web - based tool that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvirocancer immunotherapy, systems biology and bioinformatics — today announced the release of the Cancer Research Institute iAtlas, a comprehensive web - based tool that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvirsystems biology and bioinformatics — today announced the release of the Cancer Research Institute iAtlas, a comprehensive web - based tool that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenviroCancer Research Institute iAtlas, a comprehensive web - based tool that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment.

As part of our coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2 — 6 in Chicago, we are speaking with Gordon Mills, MD, PhD, chair of the department of systems biology and professor of medicine and immunology at the University of Texas MD Anderson Cancer Center in Houston, about ways to incorporate homologous recombination markers into clinical practice for ovarian cCancer Center in Houston, about ways to incorporate homologous recombination markers into clinical practice for ovarian cancercancer.

Through understanding the biology of cancer cells and their interaction with the immune system we are able to discover and trial novel therapies to induce the immune system to detect and fight cancer cells.

Krogan described the CCMI as a «cross-UC program focused on using quantitative systems tools to help understand the underlying biology behind the genomic data derived from breast, head and neck, and other cancers.»

For understanding the biology of gene - gene, gene - drug and gene - microenvironment interactions, a considerably broader range of in vitro and in vivo model systems is required — we are generating 1,000 organoid cultures from human cancers, characterising their genomes, functional dependencies and drug response, and we are expanding our in vivo models to study the interface between cancer and the immune system and microenvironment.

Dissecting these interactions with a combination of cell - biology and systems biology approaches should allow uncovering the tissue specific control mechanisms that are defective in cancer.

Topics ranging from systems and synthetic biology, digital healthcare, cancer, genomics, immunology, biological engineering, microbiology, and cell biology will be covered, but anyone interested in interdisciplinary life sciences research and its applications should attend.

An international group of scientists from 6 countries bring together their expertise to develop a combined experimental and systems biology platform for predictive modelling of cancer signalling.

Topics covered include embryonic stem cells, pluripotency, germline stem cells, tissue - specific stem cells, stem cell differentiation, epigenetics, stem cell genomics and systems biology, genome reprogramming, cancer stem cells, stem cell niches, stem - cell - based disease models, nuclear transfer technology, bioengineering, drug discovery, in vivo imaging of stem cells, therapeutic applications, regenerative medicine, clinical and translational insights, stem cell research policies, ethical issues, and technical or resource - based innovations.

The geneXplain platform is an online toolbox and workflow management system for a broad range of bioinformatic and systems biology applications that we have used for the modeling of colorectal cancer in SYSCOL.

SYSCOL — Systems biology of colorectal cancer — is a collaborative project financed by the EU Framework Programme 7.

Stephen Alexander, UK - Cannabinoid receptors, transporters, endocannabinoid turnover, hydrogen sulphide turnover Arthur Christopoulos, Australia (GPCRs Liaison)- G protein - coupled receptors; analytical pharmacology; allosteric modulation; biased agonism; drug discovery; neuropharmacology John Cidlowski, USA (NHRs Liaison)- Glucocorticoid receptor signaling; apoptosis and the immune system Anthony P. Davenport, UK (Chair Evolving Pharmacology, GPCRs Liaison) Doriano Fabbro, Switzerland - Kinases and their biology, kinase inhibitors, drug discovery, pharmacology of drugs (kinase inhibitors) in the indication oncology, biology of oncology Kozo Kaibuchi, Japan Yoshikatsu Kanai, Japan - Transporters, amino acid signals, epithelial function, cancer biology Francesca Levi - Schaffer, Israel - eosinophils and mast cells as effector cells in allergic inflammation: characterization of new receptors / ligands, hypoxia / angiogenesis and eosinophils, asthma, atopic dermatitis, allergic rhinitis, immunopharmacological modulation of allergic diseases by bispecific recombinant antibodies, bacteria interactions with eosinophils and mast cells, the allergic effector unit, mast cell derived tumors: new antibody based treatment, the allergic inflammation and the resolvome, non IgE - mediated mast cell activation in diseases Eliot H. Ohlstein, USA (Editor)- Drug discovery and development, urogenital biology, cardiovascular / metabolic medicine John A. Peters, UK (LGICs Liaison) Alex Phipps, UK - Oncology, Clinical Pharmacology, Biologics and Immunotherapy Joerg Striessnig, Austria (VGICs Liaison)- Physiology, pharmacology and pathophysiological role of voltage-gated calcium channels

New data and research approaches have created opportunities for researchers to study in detail many aspects of cancer biology, including how the normal biological programs of cell proliferation and death are altered during cancer and how the immune system responds to tumors.

In 1996, she started the Center of Excellence for Breast Cancer Care at UCSF to integrate clinical care and research, automate tools for the capture of patient and clinical data, and develop systems to tailor care to biology, patient preference, and performance.

One approach uses systems biology strategies to better understand tumor progression and resistance to cancer therapeutics as well as to identify clinically useful biomarkers.

Specifically, developing systems biology data analysis framework to quantify and model diabetes and cancer molecular pathways

Specifically, the genome - wide systems biology approaches to dissect the epigenetic processes that become abnormal when aggressive prostate cancer and melanoma initiates, rather than the reductionist «gene - by - gene» classical approaches, are urgently necessary.

We have embarked upon a systems biology initiative to investigate the role of epigenetic regulation of ncRNA / miRNA expression in these cancers, and now propose to extend this initiative from the laboratory ultimately to the bedside of patients.

JAX has particular strengths in research focused on understanding aging, behavior and addiction, computational biology, cancer, development and disease, gene expression, genetics and genomics, immunology and hematology, metabolism, microbiome, neuroscience, reproductive biology, statistical and population genetics, stem cells, systems biology, and translational medicine.

«I aim to extend the scope of current modeling schemes to large systems, and to take advantage of current available big data in the cancer biology community,» he says.

Munich, Germany About Blog Definiens mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer - relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies.

Although canine models of various cancers garner increasing interest as in vitro systems suitable for studies of basic biology and drug development, the fact that breed specificity is observed for many types of cancer has excited geneticists who are anxious to localize susceptibility genes that have proved intractable in human families and populations.

Munich, Germany About Blog Definiens mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer - relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies.

Munich, Germany About Blog Definiens mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer - relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies.

Munich, Germany About Blog Definiens mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer - relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies.

Tags for this Online Resume: cell biology, melanoma, cancer research, bioinformactics, lab manager, systems biology, cell culture, Scientist, grant writing, oncology, research investigator

Munich, Germany About Blog Definiens mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer - relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies.